These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34486382)

  • 1. An updated review of teriflunomide's use in multiple sclerosis.
    Miller AE
    Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teriflunomide in multiple sclerosis: an update.
    Miller AE
    Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Sprenger T; Kappos L; Sormani MP; Miller AE; Poole EM; Cavalier S; Wuerfel J
    Mult Scler; 2022 Oct; 28(11):1719-1728. PubMed ID: 35485424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
    Front Immunol; 2021; 12():730342. PubMed ID: 34721394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide: a review of its use in relapsing multiple sclerosis.
    Garnock-Jones KP
    CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
    Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS
    Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
    Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Williams MJ; Amezcua L; Cohan SL; Cohen JA; Delgado SR; Hua LH; Lucassen EB; Piccolo RS; Koulouris CR; Stankiewicz J
    Neurology; 2024 Aug; 103(3):e209610. PubMed ID: 39018512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X; Vermersch P; Arnold DL; Bar-Or A; Cree BAC; Cross AH; Kubala Havrdova E; Kappos L; Stuve O; Wiendl H; Wolinsky JS; Dahlke F; Le Bolay C; Shen Loo L; Gopalakrishnan S; Hyvert Y; Javor A; Guehring H; Tenenbaum N; Tomic D;
    Lancet Neurol; 2024 Nov; 23(11):1119-1132. PubMed ID: 39307151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
    J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.